Clinical trial
Efficacy of DApagliflozin on REcurrence After Catheter Ablation for Atrial Fibrillation
NCT06433479 is registered in ClinicalTrials.gov with Beijing Anzhen Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of DApagliflozin on REcurrence After Catheter Ablation for Atrial Fibrillation
- Lead sponsor
- Beijing Anzhen Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- July 15, 2024
- Completion date
- July 1, 2025
- Enrollment
- 200 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.